Cargando…

Low levels of serum IL‐39 are associated with autoimmune thyroid disease

BACKGROUND: Interleukin (IL)‐39 is a novel member of IL‐12 cytokine family, but its role in autoimmune thyroid diseases (AITD) is unclear. The aim of the present study was to determine serum levels of IL‐39 in Hashimoto's thyroiditis (HT) and Graves' disease (GD) patients. METHODS: A total...

Descripción completa

Detalles Bibliográficos
Autores principales: Weng, Linjie, Huang, Guoqing, Gong, Luping, Xu, Jialu, Mao, Yushan, Li, Yan, Li, Mingcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993603/
https://www.ncbi.nlm.nih.gov/pubmed/35182078
http://dx.doi.org/10.1002/jcla.24284
Descripción
Sumario:BACKGROUND: Interleukin (IL)‐39 is a novel member of IL‐12 cytokine family, but its role in autoimmune thyroid diseases (AITD) is unclear. The aim of the present study was to determine serum levels of IL‐39 in Hashimoto's thyroiditis (HT) and Graves' disease (GD) patients. METHODS: A total of 48 patients with HT, 50 patients with GD, and 45 healthy controls (HCs) were recruited for this study. Levels of serum IL‐39 were determined by ELISA. RESULTS: Compared with HC group, levels of serum IL‐39 in patients with HT (p < 0.05) and GD (p < 0.01) were drastically reduced. Among patients with HT, serum IL‐39 levels had a positive correlation with white blood cell count (WBC) count and free triiodothyronine level. Among patients with GD, the levels of IL‐39 in serum were positively correlated with WBC count and C‐reactive protein levels. CONCLUSIONS: IL‐39 may be a new potential predictor for patients with HT and GD.